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Abstract 
 
The citric acid cycle forms a major metabolic hub and as such it is involved in many disease states 
implicating energetic imbalance. In spite of the fact that it is being branded as a 'cycle', during hypoxia, 
when the electron transport chain does not oxidize reducing equivalents, segments of this metabolic 
pathway remain operational but exhibit opposing directionalities. This serves the purpose of harnessing 
high energy phosphates through matrix substrate-level phosphorylation in the absence of oxidative 
phosphorylation. In this mini-review these segments are appraised, pointing to the critical importance of 
the alpha-ketoglutarate dehydrogenase complex dictating their directionalities. 
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Background 
 
The citric acid cycle (Krebs, 1940a) consists of sequential, reversible and irreversible biochemical 
reactions, shown in figure 1. There are many 'entry' points to this pathway but as the name 'cycle' implies, 
there is no end: every product of a reaction is a substrate for the next one eventually leading to the 
regeneration of each one of them. An exhaustive review on the cycle is beyond the scope of the present 
material; furthermore, the focus of this review is on energy harnessing, the role of the cycle in anabolism 
is hereby ignored. Two of the several benefits of this pathway are: i) the reduction of NAD+ and FAD+ by 
the respective dehydrogenases, and ii) the generation of high energy phosphates through matrix substrate-
level phosphorylation. In the presence of oxygen, NADH and FADH2 are oxidized by the electron 
transport chain, leading to the development of an electrochemical gradient across the inner mitochondrial 
membrane. Ultimately, this electrochemical gradient is utilized by F0-F1 ATP synthase to make ATP. 
During anoxia, NADH and FADH2 cannot be oxidized by the respiratory complexes, therefore, oxidative 
phosphorylation seizes. In the sections appearing below it is reviewed how reducing equivalents may still 
get oxidized by other means for the purpose of forming high energy phosphates through matrix substrate-
level phosphorylation, causing segments of the citric acid cycle to run in different directions.   
 
A naïve look on the citric acid cycle 
 
It is unfortunate that the depiction of the citric acid cycle as a unidirectional pathway is widespread, 
whereas in fact the irreversible reactions are only those catalyzed by citrate synthase and the -
ketoglutarate dehydrogenase complex, see figure 1. Ironically, Krebs himself was proving his theory on 
the cycle by fighting opposing views of other researchers who ignored the reversibility of several steps. 
The below is an excerpt from a reply to the criticisms of F. L. Breusch and of J. Thomas (Breusch, 1937; 
Breusch, 1939; Thomas, 1939): 
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"Several of the criticisms arise solely from a misinterpretation of the theory. Thomas as well as Breusch 
draw incorrect conclusions from the theory and argue against the theory when these conclusions are not 
confirmed by their experiments. This applies, for instance, to Thomas's statement that the formation of 
malate from oxaloacetate must be inhibited by malonate if the citric acid cycle is correct. In actual fact it 
was expressly stated that the reactions succinate ↔ fumarate ↔ malate ↔ oxaloacetate are reversible, 
and that oxaloacetate can be converted into the other C4 dicarboxylic acids in two ways, either 
anaerobically, or aerobically, the first being unaffected by malonate. Thomas omitted the reversibility 
symbol (↔) in his version of the theory and hence reaches incorrect conclusions", (Krebs, 1940b). 
 
A key concept from the above excerpt is that oxaloacetate can be anaerobically converted into malate, 
fumarate, or succinate in the presence of malonate, a competitive inhibitor of succinate dehydrogenase. 
The conversion of oxaloacetate to malate to fumarate, back to malate, back to oxaloacetate, which can 
condense with acetyl-CoA to form citrate has been called 'backflux' of the citric acid cycle (Sonnewald et 
al., 1993), (Brekke et al., 2012). This backflux has been supported by mathematical models (Merle et al., 
1996a), (Merle et al., 1996b), (Oz et al., 2004), just as Krebs has purported, a concept that has been 
supported by the earliest experiments of Albert Szent-Györgyi (Szent-Gyorgyi, 1935).  
Since Krebs' discovery of the citric acid cycle, some of the remaining steps of the cycle have been proven 
to operate reversibly and in segments, the directionalities of which are dictated by the presence or absence 
of oxygen. To address this in more detail these steps are examined individually in concert with relevant 
reactions, see figure 1.  
Pyruvate is a main entry point to the citric acid cycle. In the cytosol, pyruvate may arise from lactate with 
which is in equilibrium through lactate dehydrogenase. Furthermore, pyruvate can be formed through the 
reversible cytosolic alanine aminotransferase reaction (isoform 1) (Sohocki et al., 1997), where -
ketoglutarate and alanine give rise to glutamate and pyruvate (not shown). Most notably though, pyruvate 
is formed from phosphoenolpyruvate (PEP) by pyruvate kinase (PK), catalyzing a strongly exergonic and 
irreversible reaction. In turn, PEP may originate from glycolysis, or having exited from mitochondria 
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through a phosphate/phosphoenolpyruvate antiporter, a protein with isoforms in members C, D and E of 
the solute carrier family 35 (Venter et al., 2001), (Gerhard et al., 2004), (Ota et al., 2004), (Skarnes et al., 
2011). Regeneration of pyruvate from PEP that has exited mitochondria is part of the so-called "pyruvate 
recycling pathway", elaborated below. PEP has also been shown to enter mitochondria (McCoy and 
Doeg, 1975) likely through the same antiporter, supporting citrate synthesis (Wiese et al., 1996). Pyruvate 
enters mitochondria through the recently identified pyruvate carrier incorporating MPC1 and MPC2 
(Herzig et al., 2012), (Bricker et al., 2012). In the mitochondrial matrix pyruvate may be formed through 
a mitochondrial alanine aminotransferase (isoform 2) (Yang et al., 2002). There have also been reports of 
a mitochondrial pyruvate kinase in pig liver (Pizzuto et al., 2010), Jerusalem artichoke (de Bari L. et al., 
2007), and the protozoon Toxoplasma gondii (Saito et al., 2008). It remains to be seen if a mitochondrial 
pyruvate kinase is confirmed by other, independent laboratories. 
Inside the mitochondrial matrix, pyruvate will be processed by: i) pyruvate carboxylase, ii) malic enzyme, 
iii) the pyruvate dehydrogenase complex, or iv) undergo transamination with glutamate to yield -
ketoglutarate and alanine. The enzyme methylmalonyl-CoA oxaloacetate transcarboxylase (EC 2.1.3.1) 
may also exchange pyruvate with oxaloacetate, but so far, this protein has been identified only in bacteria 
metabolizing propanoate (Swick and Wood, 1960).  
Carboxylation of pyruvate by pyruvate carboxylase yields oxaloacetate, and although this reaction is 
thermodynamically reversible (see table I), backflow towards pyruvate may occur only at a low rate 
(Freidmann et al., 1971), (McClure et al., 1971a), (McClure et al., 1971b), (Barden et al., 1972).  
Pyruvate carboxylase activity shows a remarkable cell-specific distribution in the brain: neurons appear to 
exhibit very little if at all pyruvate carboxylase activity, while astrocytes adequately express the fully 
functional enzyme (Yu et al., 1983), (Shank et al., 1985), (Cesar and Hamprecht, 1995). It has been a 
long-standing question of this author, what purpose does it serve that, neurons lack pyruvate carboxylase? 
This question is pressing, because neurons lose -ketoglutarate in the form of glutamate and GABA 
during neurotransmission, which are taken up by the astrocytes (Balazs et al., 1970), (Henn et al., 1974). 
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Evidence of neuronal pyruvate carboxylation emerged as early as 1966 (O'Neal and Koeppe, 1966), 
reviewed in (Hassel, 2001). In view of the absence of pyruvate carboxylase in neurons, alternative 
pathways were sought; it was found that neurons may carboxylate pyruvate through malic enzyme (Vogel 
et al., 1998b), (Hassel and Brathe, 2000), a reversible enzyme (Hsu and Lardy, 1969) exhibiting high 
pyruvate carboxylating activity (Salganicoff and Koeppe, 1968) that forms malate. In astrocytes, malic 
enzyme is mostly in the cytosol, while in neurons is mostly in the mitochondria (Kurz et al., 1993), 
(Bukato et al., 1994), (McKenna et al., 1995), (Vogel et al., 1998a), (Vogel et al., 1998b). However, most 
researchers consider the mitochondrial malic enzyme to operate in the decarboxylating direction in the 
brain (Vogel et al., 1998b), (Hertz et al., 1999), (McKenna et al., 2000). Furthermore, the group of 
Sonnewald concluded that neuronal pyruvate carboxylation is unlikely to be of quantitative significance 
(Waagepetersen et al., 2001); likewise, (Lieth et al., 2001) found that no pyruvate carboxylation occurs in 
neurons. It appears that the chapter on neuronal pyruvate carboxylation is still open. On the other hand, 
irreversible decarboxylation of pyruvate catalyzed by the pyruvate dehydrogenase complex yielding 
acetyl-CoA occurs in mitochondria of all cell types. Acetyl-CoA is also an indispensable activator of 
pyruvate carboxylase, see (Adina-Zada et al., 2012) and references therein. The oxaloacetate formed from 
pyruvate carboxylase will have four fates: i) it will get reversibly decarboxylated by a mitochondrial 
phosphoenolpyruvate carboxykinase, an enzyme that has been cloned and adequately characterized 
(Modaressi et al., 1996), (Modaressi et al., 1998); ii) it may get transaminated with glutamate, yielding -
ketoglutarate and aspartate; iii) it may get converted to malate, through MDH; or iv) condense with 
acetyl-CoA to form citrate, a reaction catalyzed by citrate synthase. The latter reaction is irreversible, and 
represents the first committed step to citric acid cycle.  
Citrate will then get converted to isocitrate by aconitase in a reversible reaction, which will then be 
dehydrogenated to -ketoglutarate by isocitrate dehydrogenase (IDH). There are two mitochondrial IDH 
isoforms: IDH2, which is NADP+-dependent and reversible (Des Rosiers C. et al., 1995; Lemons et al., 
2010; Metallo et al., 2009; Metallo et al., 2012; Yoo et al., 2008), and IDH3 (Ehrlich and Colman, 1983), 
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(Des Rosiers C. et al., 1994), (Comte et al., 2002) which is NAD+-dependent, and considered irreversible 
(Gabriel et al., 1986). Splice variants have also been identified (Okamoto et al., 2003), (Kim et al., 1999). 
IDH1, which is NADP+-dependent and reversible (Londesborough and Dalziel, 1968) is expressed 
predominantly in the cytosol (Nekrutenko et al., 1998). The reversibility of mitochondrial IDH has been 
inferred from experiments in isolated nerve from lobsters, bullfrogs and rabbits (Waelsch et al., 1965), 
and further on demonstrated in striatal slices (Cheng and Nakamura, 1972), cortical slices (Nakamura et 
al., 1970), (Patel, 1974b) brain homogenates (Salganicoff and Koeppe, 1968), rat liver (Des Rosiers C. et 
al., 1995) and rat heart (Randle et al., 1970), (Comte et al., 2002). Despite the fact that IDH3 is highly 
regulated by a variety of effectors (Gabriel et al., 1986), from the above an obvious futile cycle can be 
discerned, where isocitrate (plus NAD+) is oxidatively decarboxylated to -ketoglutarate (plus NADH) by 
IDH3, and then IDH2 may reverse this by converting -ketoglutarate plus NADPH to isocitrate plus 
NADP+; it has been proposed that this futility, in concert with the function of a proton-translocating 
transhydrogenase, fine-tune the citric acid cycle or produce heat, thereby contributing to thermoregulation 
in the animal at the expense of the transmembrane proton electrochemical potential gradient, or even 
contribute to the regulation of 'leak' currents across the inner mitochondrial membrane (Sazanov and 
Jackson, 1994). This is theoretically possible because the catalytic site of the transhydrogenase for 
oxidation and reduction of the nicotinamide nucleotides is facing the matrix, thus membrane potential 
generated by the respiratory chain is consumed during the reduction of NADP+ or NAD+ by NADH or 
NADPH, respectively (Jackson, 1991), which can be accounted as a 'leak' pathway, therefore contributing 
to metabolic thermogenesis. By the same token, membrane potential can be generated during the reverse 
operation, thereby decreasing this leak pathway, hence minimizing metabolic thermogenesis. Since the 
transhydrogenase links the redox state of NAD+ and NADP+ to membrane potential to the concerted 
actions of IDH2 and IDH3, it is conceivable that the transhydrogenase may impose on the rate of IDH 
reaction, effectively controlling the rate of the overall citric acid cycle. These theoretical considerations 
elaborated by Sazanov and Jackson could be easily tested since C57Bl/6J mice do not express the 
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transhydrogenase, while mice belonging to any of the following strains: C57BL/6JEi, C57BL/6N, 
C57BL/6NJ, C57BL/6ByJ, C57BL/10J, C57L/J, or C58/J express this protein (Toye et al., 2005). To the 
best of my knowledge, the results of such an experiment do not exist in the literature.  
Apart from regenerating isocitrate by IDH2, -ketoglutarate could have three fates: i) transamination with 
aspartate, yielding oxaloacetate and glutamate, ii) dehydrogenation by glutamate dehydrogenase yielding 
glutamate, or iii) decarboxylation by KGDHC yielding succinyl-CoA. The reaction catalyzed by KGDHC 
requires CoASH and NAD+, is irreversible, and represents the second commitment step in the citric acid 
cycle. KGDHC deserves particular attention: this enzyme complex is subject to tight regulation: it is 
inhibited by increased [succinyl-CoA]/[CoA] and [NADH]/[NAD+] ratios (Garland and Randle, 1964), 
(Hamada et al., 1975), (McMinn and Ottaway, 1977), (LaNoue et al., 1983), (Markiewicz and Strumilo, 
1995); it exhibits a biphasic response to Ca2+, low concentrations activating the complex (McCormack 
and Denton, 1979), (Lawlis and Roche, 1981) (McCormack and Denton, 1989), (Wan et al., 1989), 
(Panov and Scarpa, 1996) while high concentrations of the cation inhibit it (Lai and Cooper, 1986). The 
regulation of KGDHC reaction by the above and other effectors such as adenine nucleotides, pH and 
Mg2+ has been reviewed by (Strumilo, 2005) and (Starkov, 2012) and  modeled by the group of Beard (Qi 
et al., 2011). The citric acid cycle is indeed regulated at several steps (LaNoue et al., 1970), (LaNoue et 
al., 1983), (Bukato et al., 1995), (Gibala et al., 2000), (Pagliarini and Dixon, 2006), (McKenna, 2007); 
furthermore, different intermediates of the cycle exert different regulation depending on target isoform 
and tissue distribution (McKenna et al., 1995), (McKenna et al., 2000); equally importantly, the cycle is 
modulated by regulating the transport of substrates that enter the cycle (Safer and Williamson, 1973). 
However, it is KGDHC that exhibits the highest flux-control coefficient of the citric acid cycle (Patel, 
1974a), (Cooney et al., 1981), (Taegtmeyer, 1983), (Russell, III and Taegtmeyer, 1991), (Russell, III and 
Taegtmeyer, 1992) (Sheu and Blass, 1999). From the factors mentioned to regulate KGDHC reaction, two 
of them are emphasized: CoASH and NAD+. Availability of CoASH is known to limit KGDHC reaction 
(HUELSMANN et al., 1964), (Taegtmeyer, 1983), (Russell, III and Taegtmeyer, 1991), (Russell, III and 
Taegtmeyer, 1992). The availability of CoASH and the competition for it between pyruvate 
 8
          Direction of Krebs cycle 
dehydrogenase (PDH) and KGDHC (HUELSMANN et al., 1964), (Randle et al., 1970), led to the 
suggestion that the citric acid cycle operates in two sequential segments; the first being from acetyl-CoA 
until -ketoglutarate, (CoASH required for the PDH reaction), and the second one being from -
ketoglutarate to oxaloacetate (CoASH required for the KGDHC reaction), (Randle et al., 1970). This was 
probably the first notion implying that the citric acid cycle may run in segments. Regarding NAD+ 
availability, it is already a textbook definition that NADH oxidized by the respiratory complexes yields 
NAD+, which will be re-reduced by the dehydrogenases of the cycle. However, as mentioned above, 
during hypoxia, when the electron transport chain is not operational, NADH may get oxidized by other 
means such as by the reverse operation of malate dehydrogenase, forming malate from oxaloacetate. This 
concept forms the basis for the continuous operation of KGDHC during hypoxia and will be discussed in 
greater detail below, (see under "What happens to NADH during hypoxia?").   
The product of KGDHC, succinyl-CoA is the substrate for 'substrate-level phosphorylation" performed by 
succinate thiokinase, a reversible enzyme (also known as succinyl-CoA ligase). Succinate thiokinase is a 
heterodimer enzyme being composed of an invariant α subunit encoded by SUCLG1 and a substrate-
specific β subunit, encoded by either SUCLA2 or SUCLG2. With the input of inorganic phosphate this 
dimer combination results in either an ATP-forming SUCL (EC 6.2.1.5) or a GTP-forming SUCL (EC 
6.2.1.4). GTP may transphosphorylate to ATP by nucleoside-diphosphate kinase. In either case, succinate 
thiokinase also generates CoASH and succinate. Generation of high-energy phosphates by this reaction 
proceeds even in the absence of oxygen and perhaps under these conditions with a higher rate, because 
hypoxia activates the enzyme (Phillips et al., 2009). This concept will be reviewed in more detail below, 
(see under " Hypoxia: all roads lead to succinate?"). 
Succinate will be processed by the reversible succinate dehydrogenase to yield fumarate, and since this 
protein is also respiratory complex II, FAD+ will be reduced to FADH2. Fumarate is in equilibrium with 
malate through the reaction catalyzed by fumarase, an enzyme that is also found in the cytosol (Raimundo 
et al., 2011).  
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Malate that emerges from fumarase will have two fates, both catalyzed by reversible reactions: i) 
dehydrogenation by malate dehydrogenase to oxaloacetate, thereby completing the citric acid cycle or ii) 
decarboxylation by malic enzyme to pyruvate; this reaction is part of the 'pyruvate-recycling pathway', 
see below under "The 'pyruvate-recycling pathway'". 
Apart from the mitochondrial malate dehydrogenase, there is a cytosolic malate dehydrogenase; both 
enzymes contribute to the operation of the malate-aspartate shuttle (Borst, 1962). In addition to these two 
malate dehydrogenases, the shuttle recruits aspartate aminotransferases in the mitochondrial matrix and in 
the cytosol, the malate--ketoglutarate antiporter and glutamate-aspartate antiporter in the inner 
mitochondrial membrane. The shuttle mediates the transfer of NADH from the cytosol formed in i) the 
glyceraldehyde-3-phosphate dehydrogenase reaction in the glycolysis and ii) that coming from oxidation 
of lactate by the lactate dehydrogenase reaction to pyruvate, into the mitochondrial matrix. Through 
augmented transamination of aspartate and -ketoglutarate, the malate-aspartate shuttle has been 
implicated in a cascade of metabolic reactions leading to anaerobic production of ATP (Pisarenko et al., 
1995), see below under "Hypoxia: all roads lead to succinate?". Blockade of the shuttle by the 
transaminase inhibitor aminooxyacetate (Kauppinen et al., 1987) during ischemia and at the beginning of 
reperfusion confered cardioprotection in ischemia–reperfusion injury similar to that observed during 
ischemic preconditioning (Stottrup et al., 2010). However, sustained inhibition of the shuttle during 
reperfusion carried a negative outcome (Lofgren et al., 2010). As a word of caution, inhibiting 
transamination with aminooxyacetate confers very different effects on the oxidation of energy substrates 
in different preparations, suggesting different regulation of metabolism (McKenna et al., 1993).  
 
The 'pyruvate-recycling pathway' 
 
The 'pyruvate-recycling pathway' was described in liver and kidney 40 years ago (Freidmann et al., 1971), 
(Cohen, 1987), (Rognstad and Katz, 1972), discovered as part of the dicarboxylic acid cycle (Freidmann 
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et al., 1971). Later on, it was found to operate in brain tissue (Cerdan et al., 1990), (Kunnecke et al., 
1993), where it has been extensively characterized, (Bakken et al., 1997a), (Haberg et al., 1998), and 
especially in astrocytes (Bakken et al., 1997b),. Basically, it refers to the fact that downstream metabolism 
of pyruvate will eventually regenerate pyruvate. This may occur either through PC forming oxaloacetate, 
that in turn will form PEP through mitochondrial PEPCK, and then PEP will exit mitochondria, where it 
can regenerate pyruvate through PK. GTP for the mitochondrial PEPCK may originate from the GTP-
forming succinate thiokinase, see below and (Stark et al., 2009). Alternatively, oxaloacetate will be 
reduced to malate through malate dehydrogenase (MDH) that will be then catalyzed by malic enzyme 
yielding pyruvate. The pathway followed for recycling of pyruvate will depend on the tissue because of 
the tissue-dependent distribution, regulation and equilibria of the participating enzymes.  
 
What happens to NADH during hypoxia? 
 
The reversibility of MDH not only assists in the completion of the 'pyruvate-recycling pathway', it also 
contributes to re-oxidation of NADH when the electron transport chain is inhibited due to lack of oxygen. 
Having said that, the question arises, why is there a need for continuing oxidation of NADH? As 
mentioned above, the citric acid cycle not only provides reducing equivalents for the respiratory 
complexes, it also generates high energy phosphates through matrix substrate-level phosphorylation. This 
occurs at the level of succinate thiokinase. However, since this is a highly reversible reaction, formation 
of ATP or GTP will happen only if the equilibrium favors succinate production and succinyl-CoA is 
readily available. Succinyl-CoA may arise from either propionyl-CoA metabolism, or KGDHC; provision 
of succinyl-CoA through KGDHC is much higher than that originating from propionyl-CoA metabolism 
(Stryer L, 1995). For KGDHC to operate, the inputs of CoASH, -ketoglutarate and NAD+ are necessary. 
-ketoglutarate may arise from glutamate, an amino acid which is abundant in at least two pools in the 
CNS (McKenna, 2007). CoASH will re-emerge from succinate thiokinase, if the equilibrium favors ATP 
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or GTP production (Allen and Ottaway, 1986). Therefore, the key ingredient is NAD+. Formation of 
NAD+ through MDH, converting oxaloacetate to malate is a viable possibility. Indeed, MDH is known to 
be upregulated in KGDHC deficiencies (Bubber et al., 2011), (Shi et al., 2008), (Bubber et al., 2005), (Shi 
and Gibson, 2011). Another viable possibility that, to the best of my knowledge, has not been adequately 
characterized is NADH oxidation by mitochondrial diaphorases. This concept has been cultivated by the 
group of Iaguzhinskii, where the stimulatory effect of diaphorase substrates was examined during 
cyanide-resistant respiration of isolated mitochondria (Kolesova et al., 1987), (Kolesova et al., 1989), 
(Kolesova et al., 1991), (Kolesova et al., 1993). Whichever the source of NAD+, the continuous operation 
of KGDHC will supply succinate thiokinase with succinyl-CoA that will generate high-energy 
phosphates, and succinate. The high-energy phosphates will support the hydrolytic function of the Fo-F1 
ATPase which operates in reverse during anoxic conditions, thus maintaining a modest membrane 
potential (Rouslin et al., 1986), (Rouslin et al., 1990). Generation of high-energy phosphates in the 
mitochondrial matrix will also lead to an increase of their local concentration, thereby maintaining the 
reversal potential of the adenine nucleotide translocase in a range (termed the 'B space' of mitochondrial 
phosphorylation) where it will prevent the translocase from reversing, hence sparing the 
extramitochondrial ATP pools from mitochondrial consumption (Chinopoulos et al., 2010), 
(Chinopoulos, 2011a), (Chinopoulos, 2011b). 
 
Hypoxia: all roads lead to succinate? 
  
From the above one may deduce that during hypoxia, the segment [-ketoglutarate → succinyl-CoA → 
succinate] may 'collide' with the product of malate dehydrogenase towards NAD+ formation -malate- 
which is in equilibrium with fumarate and succinate, since both fumarase and succinate dehydrogenase 
catalyze reversible reactions, a consideration that has been well established to occur in vivo (Brekke et al., 
2012). This would practically mean that succinate is a 'dead-end' metabolite in hypoxia. Activity of the 
citric acid cycle in anoxia has been unequivocally demonstrated in 1966 (Randall, Jr. and Cohen, 1966). 
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Anaerobic metabolism was found to change the level of citric acid cycle intermediates during the first few 
seconds (Goldberg et al., 1966) and even more so within the first few minutes (Norberg and Siesjo, 1975). 
Accumulation of succinate as an end product of anaerobic metabolism of glutamate was hypothesized 
even before the discovery of the citric acid cycle (Needham, 1930), a hypothesis that received solid 
foundation as early as 1937 (Weil-Malherbe, 1937), still prior to the establishment of the cycle. Since 
then, many publications emerged in the literature in support of this hypothesis: succinate was reported to 
accumulate in several hypoxic tissues (Hoberman and Prosky, 1967), (Folbergrova et al., 1974), 
(Freminet et al., 1980), (Freminet, 1981), (Benzi et al., 1982), (Pisarenko et al., 1986). This accumulation 
of succinate was associated with fumarate reduction and -ketoglutarate oxidation (HUNTER, Jr., 1949), 
(Chance and HOLLUNGER, 1960), (Randall, Jr. and Cohen, 1966), (SANADI and FLUHARTY, 1963) 
(Penney and Cascarano, 1970), (Wilson and Cascarano, 1970), (Taegtmeyer et al., 1977b) (Taegtmeyer, 
1978). Succinate accumulates during anaerobic exercise, and also in diving animals (Hochachka and 
Dressendorfer, 1976), (Hochachka and Storey, 1975) and invertebrates performing facultative 
anaerobiosis (Hochachka and Mustafa, 1972). As early as 1949, it was recognized that anaerobic 
mitochondrial metabolism can generate ATP and maintain mitochondrial energization via substrate-level 
phosphorylation during the conversion of α-ketoglutarate to succinate (HUNTER, Jr., 1949), (Gronow 
and Cohen, 1984), (Penney and Cascarano, 1970), (Peuhkurinen, 1982), (Snaith et al., 1992). The benefits 
of mitochondrial substrate-level phosphorylation substantiated by the shift of equilibrium of the succinate 
thiokinase reaction towards succinate accumulation during anaerobiosis have been also demonstrated in 
hemorrhagic shock (Chick et al., 1968), and in hypoxic injury of the proximal kidney tubules (Weinberg 
et al., 2000b). During oxygen deprivation, an increase in glutamate utilization has been observed in 
several mammalian tissues, sometimes to the point of depletion (Williamson et al., 1967), (Edington et 
al., 1973), (Gailis and Benmouyal, 1973), (Taegtmeyer et al., 1977a) (Taegtmeyer et al., 1977b), 
(Pisarenko et al., 1987). In cardiac ischemia, malate increases 4-fold (Pisarenko et al., 1988), together 
with pronounced conversion of -ketoglutarate to succinate (Peuhkurinen et al., 1983), (Sanborn et al., 
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1979), (Pisarenko et al., 1985), (Pisarenko et al., 1987); as a result, succinate exits the ischemic organ 
(Pisarenko et al., 1988). Succinate can be transported out of mitochondria in exchange of malate or 
inorganic phosphate (LaNoue et al., 1970), though its transport is relatively slow (Jans and Willem, 
1991). Increased myocardial uptake of glutamate was demonstrated in humans after myocardial hypoxic 
episodes (Mudge, Jr. et al., 1976), (Thomassen et al., 1983). This was later confirmed in a rat (Pisarenko 
et al., 1985), and dog model (Lazar et al., 1980). However, it must also be pointed out that in cell cultures 
of astrocytes exposed to hypoxia, NMR spectroscopic studies reported no accumulation of succinate 
(Sonnewald et al., 1994), nor increased consumption of glutamate (Bakken et al., 1998).    
In view of the fact that supporting the conversion of -ketoglutarate and its precursors to succinate 
benefits anaerobic metabolism in many tissues, several regimens boosting substrate-level phosphorylation 
have been examined, with impressive outcomes: exogenous glutamate, aspartate, and -ketoglutarate 
were reported to improve the performance of anoxic or ischemic myocardium via mitochondrial synthesis 
of ATP coupled to succinate and alanine formation (Pisarenko et al., 1983) (Pisarenko et al., 1985), (Bittl 
and Shine, 1983), (Matsuoka et al., 1986). Provision of -ketoglutarate during blood cardioplegia 
improved myocardial protection in patients undergoing coronary operations (Kjellman et al., 1995), 
(Kjellman et al., 1997). Infusion with -ketoglutarate after coronary operation in patients that underwent 
cardiopulmonary bypass enhanced renal blood flow (Jeppsson et al., 1998). Fibroblasts from patients with 
no F0-F1 ATPase activity could be rescued by administration of -ketoglutarate plus aspartate (Sgarbi et 
al., 2009). Beneficial effects of -ketoglutarate plus aspartate were also shown in hypoxic kidney 
proximal tubules, with an associated increase in succinate formation (Weinberg et al., 2000a). However, 
perfusion of ischemic kidney with -ketoglutarate and malate, worsened the situation (Bienholz et al., 
2012), possibly due to cardiovascular depressive effects.  
The question arises, what will happen with all this succinate? Succinate exits mitochondria and will 
inhibit HIF- prolyl hydroxylase, thereby stabilizing and activating HIF-1, initiating a hypoxic response 
(Selak et al., 2005), (Semenza, 2007); this phenomenon is extremely important in tumorigenesis 
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(Raimundo et al., 2011). Furthermore, succinate (as well as -ketoglutarate) have been found to act as 
ligands for G-coupled receptors, outside the cell (He et al., 2004), (Deen and Robben, 2011). From the 
metabolic point of view, succinate could only be metabolized when the electron transport chain regains 
functionality when adequate oxygen concentrations are restored, and follow the route towards fumarate 
→ malate → oxaloacetate generating FADH2 and NADH in the process, or malate → pyruvate, 
generating NADPH through malic enzyme. Perhaps succinate accumulation contributes to 
hyperventilation after anaerobic exercise?  
One very important aspect of metabolism of succinate upon restoration of anaerobiosis, is the potential for 
forming reactive oxygen species in excess (Starkov, 2008). Catabolism of succinate by mitochondria 
exhibiting a sufficiently high membrane potential leads to generation of hydrogen peroxide and 
superoxide radical (Korshunov et al., 1997); there are a number of reviews on this subject, the reader is 
referred elsewhere (Brand et al., 2004), (Andreyev et al., 2005), (Adam-Vizi and Chinopoulos, 2006), 
(Drose and Brandt, 2012). 
 
Can succinate formation through the 'NAD+-fumarate reductase system' generate ATP through the 
forward operation of the F0-F1 ATP synthase during hypoxia? 
 
The conversion of fumarate to succinate as part of an own entity, termed the 'NAD+-fumarate reductase 
system' has been reported to exist in bacteria, lower eucaryotes, shellfish and cancer cells (Kroger et al., 
1992), (Kita et al., 2007), (Tomitsuka et al., 2009) (Tomitsuka et al., 2010), (Tomitsuka et al., 2012), 
composed of complex I and the reverse reaction of complex II. This system does not need oxygen, and 
only complex I functions as a proton pump; it has been suggested that during anaerobiosis, the ensuing 
formation of a transmembrane electrochemical proton gradient through this system supports ATP 
synthesis by F0-F1 ATP synthase. However, in my opinion, in mammalian mitochondria this system 
cannot support formation of ATP through the F0-F1 ATP synthase, for the following reasons: i) the 
oxidation of FADH2 to FAD+ by SDH associated with conversion of fumarate to succinate and oxidation 
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of ubiquinol (QH2) to ubiquinone (Q) by FAD+ is possible, however, downstream interactions of Q with 
complex I does not necessarily translate to proton pumping through this complex by this mechanism; ii) 
nonetheless, assuming that proton pumping may occur at the level of complex I by this mechanism, when 
complexes III and IV are not pumping any protons, this is not sufficient for generating a membrane 
potential that would exceed the reversal potential of the F0-F1 ATP synthase (Chinopoulos et al., 2010), 
(Chinopoulos, 2011a); therefore F0-F1 ATP synthase would still pump protons out of the matrix, 
hydrolyzing ATP in the process; iii) in the experiments outlined in (Chinopoulos et al., 2010) using 
respiration-impaired mammalian mitochondria where the concept of the 'NAD+-fumarate reductase 
system' could be considered, ATP was formed in the mitochondrial matrix by succinate thiokinase in the 
presence of rotenone; in this case, complex I was completely blocked and therefore an 'NAD+-fumarate 
reductase system' is redundant. Likewise, in a study on ischemic myocardium (Peuhkurinen et al., 1983) 
the potential energy-yielding reduction of fumarate to succinate was found to be insignificant. Perhaps in 
bacteria, lower eucaryotes and cancer cells other kind of ubiquinone analogues are operational, that 
thermodynamically may support the 'NAD+-fumarate reductase system', and there are evidence in support 
of this notion (Tomitsuka et al., 2012), (Tomitsuka et al., 2009), (Tomitsuka et al., 2010).  
 
Citric acid cycle: the segments 
 
From the above considerations one can deduce three segments of the citric acid cycle: 
 
(1) Oxaloacetate + acetyl-CoA→ citrate ↔ isocitrate ↔ -ketoglutarate 
(2) -ketoglutarate → succinyl CoA ↔ succinate 
(3) Oxaloacetate ↔ malate ↔ fumarate ↔ succinate 
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Segment (1) may occur towards the direction of -ketoglutarate synthesis only during aerobic 
metabolism; acetyl-coA will originate from pyruvate through PDH or from fatty acids, and it will reach 
KGDHC, the enzyme expressing the highest flux-control coefficient of the citric acid cycle. The two key 
components dictating if KGDHC will be operational are CoASH and NAD+. During anaerobiosis, -
ketoglutarate (that may originate from glutamine and/or glutamate) may also backflux to isocitrate, which 
is in equilibrium with citrate (Comte et al., 2002), (Des Rosiers C. et al., 1995), (Des Rosiers C. et al., 
1994).  
During aerobiosis, segment (2) will commence, where -ketoglutarate will be metabolized by KGDHC, 
until the emergence of succinate. In anaerobiosis, segment (2) will commence only if sufficient CoASH 
and NAD+ are available. It is highly likely that during anaerobiosis NAD+ will originate from MDH, 
operating towards malate formation. 
The magnitude of succinate concentration emerging from segment (2) will be 'weighted' against that 
coming from segment (3), where all participating substrates appear to exist in equilibrium. In aerobic 
metabolism, the formation of oxaloacetate is favored. In anaerobic conditions, succinate formation is 
favored. The direction favored during anaerobiosis generates NAD+, which is critical for the operation of 
KGDHC, which will supply succinyl CoA to succinate thiokinase that will yield high-energy phosphates 
also regenerating CoASH. 
From the above, it is obvious that KGDHC plays a critical role in determining whether a segment will be 
operational, and if yes, towards which direction, see figure 2. Bearing that in mind, the question arises as 
to the usefulness of this information. For once, increased flux of KGDHC by substrates such -
ketoglutarate or glutamate has shown a beneficial outcome in diverse pathological situations involving 
hypoxia, see above, " Hypoxia: all roads lead to succinate?". Secondly, certain pathological conditions 
may emerge by inhibition of KGDHC, either by reactive oxygen species made elsewhere, or by the 
enzyme complex itself (Starkov et al., 2004), (Tretter and Adam-Vizi, 2004) upon reoxygenation, or by 
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inherent mutations of a gene encoding at least one of the subunits of the complex (Ambrus et al., 2011), 
reviewed in (Starkov, 2012).  
 
Conclusions 
 
On 1953, when Hans Krebs was cycling down the stairs on the right to climb them up again on the left in 
order to receive the Nobel Prize from King Gustaf VI for "his discovery of the citric acid cycle", little did 
he know that nearly 60 years later there would be a flare of interest to investigate the cycle and its 
directionality in vivo (Schroeder et al., 2009), (Chen et al., 2012), (Zacharias et al., 2012), 
(http://www.nobelprize.org/mediaplayer/index.php?id=633). The benefits of knowing the directionality of 
the cycle during hypoxia are elaborated above, however, a field that gains momentum rapidly involves the 
adulteration of this biochemical pathway for the purpose of cancer cell survival (Wise et al., 2011), 
(Mullen et al., 2012). It is perhaps in this pathway where cancer finds metabolic support when growing in 
hypoxic environments, while also exhibiting a number of defects in the electron transport chain 
(Tomlinson et al., 2002), (Hao et al., 2009), (Linehan et al., 2010), (Weinberg et al., 2010) rendering its 
harboring mitochondria as defective. The latest findings pave exciting new ways for researching on one of 
the most fundamental discovery of biochemistry, the citric acid cycle.  
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Table I: Thermodynamic properties of selected enzymatic reactions of the citric acid cycle and related 
reactions, adapted from (Li et al., 2011) and (Stryer L, 1995). The conditions are as follows: 
T = 310.15 K, I = 0.18 M, pH = 7, [Mg2+] = 0.8 mM, [K+] = 140 mM, [Na+] = 10 mM, [Ca2+] = 0.0001 mM. 
Values in bold indicate irreversible reactions. A negative (-) sign indicates that the reaction is favored 
towards formation of the products. A positive (no sign) indicates that the reaction is favored towards 
formation of the substrates. For each enzyme, metabolites considered as substrates are indicated in the 
parentheses: PEPCK (PEP), PK (PEP), PC (pyruvate), PDH (pyruvate), CS (OAA and Acetyl-CoA), AC 
(citrate), IDH (isocitrate), KGDHC (-ketoglutarate), STK (succinyl-CoA), SDH (succinate), FSE 
(fumarate), MDH (malate), ME (malate), and GDH (glutamate).   
Enzyme  Free energy (kJ/mol) 
Phosphoenolpyruvate carboxykinase 0.90 
Pyruvate kinase -31.40 
Pyruvate carboxylase -4.57 
Pyruvate dehydrogenase -39.26 
Citrate synthase -36.60 
Aconitase -7.58 
Isocitrate dehydrogenase (NAD+-forming) -20.90 
Isocitrate dehydrogenase (NADP+-forming) -8.40 
-ketoglutarate dehydrogenase complex -37.66 
succinate thiokinase 0.07 
succinate dehydrogenase -0.59 
Fumarase -3.52 
Malate dehydrogenase 28.04 
Malic enzyme 2.00 
Glutamate dehydrogenase 15.50 
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Legend to figures: 
 
Figure 1: The citric acid cycle and related reactions. In black arrows, reversible reactions are shown. 
Irreversible reactions are drawn in red arrows. Enzymes of the cycle are highlighted in blue. PEP: 
phosphoenolpyruvate; PK: pyruvate kinase; LDH: lactate dehydrogenase; FA: fatty acids; ME; malic 
enzyme; PDH: pyruvate dehydrogenase; PEPCK: phosphoenolpyruvate carboxykinase; PC: pyruvate 
carboxylase; CS: citrate synthase; ASAT: aspartate aminotransferase; AC: aconitase; GDH: glutamate 
dehydrogenase; IDH: isocitrate dehydrogenase; KGDHC: -ketoglutarate dehydrogenase complex; STK: 
succinate thiokinase; SDH; succinate dehydrogenase; FSE: fumarase; MDH; malate dehydrogenase; GS: 
glutamine synthetase; GLS: glutaminase. 
 
Figure 2: Reactions of the citric acid cycle and related pathways during ischemia and/or anoxia. Enzymes 
of the cycle are highlighted in blue. Non-operational pathways during ischemia and/or anoxia are depicted 
in grey dotted lines.  
 
 


